# RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

> **NCT00968253** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Everolimus (RAD001)
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Dexamethasone
- **DRUG:** Mesna
- **DRUG:** Methotrexate
- **DRUG:** Ara-C (Cytarabine)
- **DRUG:** Methylprednisone
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT00968253
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968253, "RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00968253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*